As of October 27, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of 10x Genomics, Inc. The largest reported stake is Fmr LLC's, at 15.6%. 20 filings are on record since July 16, 2025 (Schedule 13G/A, March 6, 2026).
Sell to companies like 10x Genomics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: ARK Investment Management LLC · Percent: 5.22% · SCHEDULE 13G/A
- · Holder: T. Rowe Price Associates, Inc. · Percent: 11.7% · SCHEDULE 13G
- · Holder: ARK Investment Management LLC · Percent: 8.56% · SCHEDULE 13G/A
- · Holder: Vanguard Capital Management · Percent: 5.24% · SCHEDULE 13G
- · Holder: Vanguard Portfolio Management · Percent: 5.93% · SCHEDULE 13G
10x Genomics, Inc. has 20 Schedule 13D or 13G filings on record since 2025-07-16. 6 holders' latest filing reports 5% or more of class a common stock, $0.00001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 15.6% | 18,543,562 | SCHEDULE 13G/A, 2026-03-06 | 2026-02-27 |
| T. Rowe Price Associates, Inc. | 11.7% | 14,044,020 | SCHEDULE 13G, 2026-09-08 | 2026-08-31 |
| BlackRock, Inc. | 7.6% | 8,496,636 | SCHEDULE 13G/A, 2025-07-16 | 2025-06-30 |
| Vanguard Portfolio Management | 5.93% | 6,981,683 | SCHEDULE 13G, 2026-04-28 | 2026-03-31 |
| Vanguard Capital Management | 5.24% | 6,166,597 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| ARK Investment Management LLC | 5.22% | 6,272,998 | SCHEDULE 13G/A, 2026-10-07 | 2026-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | 4.7% | 5,381,219 | SCHEDULE 13G/A, 2025-10-27 | 2025-09-30 |
| Amova Asset Management Americas, Inc. | 4.7% | 5,376,883 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| Millennium Management LLC | 2.7% | 3,060,859 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-25 | 2026-03-13 |
Holding shares or following this stake? See who's behind 10x Genomics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on 10x Genomics, Inc. and the records around it.
10x Genomics, Inc. elsewhere on the record
Companies that share a holder
- Amova Asset Management Americas, Inc. also filed stake reports on 3 other companies: Ibotta, Inc. (Feb 2026), Nextdoor Holdings, Inc. (Feb 2026), Arcturus Therapeutics Holdings Inc. (Nov 2025)
- Sumitomo Mitsui Trust Group, Inc. also filed stake reports on 6 other companies: ORIX Corporation (Jul 2026), GCM Grosvenor Inc. (Apr 2026), Schrodinger, Inc. (Apr 2026)
- ARK Investment Management LLC also filed stake reports on 20 other companies: Twist Bioscience Corp (Sep 2026), 908 Devices Inc. (Aug 2026), Beam Therapeutics Inc. (Aug 2026)
Watch 10x Genomics, Inc.
Get an email when 10x Genomics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on 10x Genomics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on 10x Genomics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 10x Genomics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 7.6% | SCHEDULE 13G/A |
| 2025-07-31 | Sumitomo Mitsui Trust Group, Inc. | 5.4% | SCHEDULE 13G |
| 2025-08-06 | Fmr LLC | 8.8% | SCHEDULE 13G/A |
| 2025-08-07 | Fmr LLC | 10.3% | SCHEDULE 13G/A |
| 2025-08-12 | Millennium Management LLC | 2.7% | SCHEDULE 13G/A |
| 2025-08-13 | Nikko Asset Management Americas, Inc. | 5.4% | SCHEDULE 13G |
| 2025-10-27 | Sumitomo Mitsui Trust Group, Inc. | 4.7% | SCHEDULE 13G/A |
| 2025-10-30 | The Vanguard Group | 11.6% | SCHEDULE 13G/A |
| 2025-11-04 | ARK Investment Management LLC | 10.39% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 8.1% | SCHEDULE 13G/A |
| 2025-11-13 | Amova Asset Management Americas, Inc. | 4.7% | SCHEDULE 13G/A |
| 2026-01-08 | Fmr LLC | 10.8% | SCHEDULE 13G/A |
| 2026-03-06 | Fmr LLC | 15.6% | SCHEDULE 13G/A |
| 2026-03-24 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-03-25 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-28 | Vanguard Portfolio Management | 5.93% | SCHEDULE 13G |
| 2026-04-29 | Vanguard Capital Management | 5.24% | SCHEDULE 13G |
| 2026-08-14 | ARK Investment Management LLC | 8.56% | SCHEDULE 13G/A |
| 2026-09-08 | T. Rowe Price Associates, Inc. | 11.7% | SCHEDULE 13G |
| 2026-10-07 | ARK Investment Management LLC | 5.22% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for 10x Genomics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.